Table 3: Follow-up at 30 days and 12-month.
| 30-day | Overall (n = 71) | MitraClip Group (n = 40) | No MitraClip Group (n = 31) | p-value |
| Primary Endpoint, n (%) | 6 (8.5%) | 2 (5%) | 4 (12.9%) | 0.393 |
| Death, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | - |
| HF Hospitalization, n (%) | 6 (8.5%) | 2 (5%) | 4 (12.9%) | 0.393 |
| NHYA Class | 2 (1-2) | 1 (1-2) | 2 (2-3) | 0.127 |
| NYHA III-IV, n (%) | 14 (19.7%) | 9 (22.5%) | 5 (16.1%) | 0.561 |
| LVEF (%) | 28 (24-35) | 25 (21-32) | 30 (25-36) | 0.033 |
| EDV-LV (ml) | 193 (142-247) | 193 (142-247) | 180 (113-230) | 0.071 |
| ESV-LV (ml) | 130 (91-180) | 155 (94-200) | 110 (80-160) | 0.070 |
| sPAP (mmHg) | 40 (30-50) | 40 (35-50) | 32 (25-40) | 0.007 |
| Mild-Moderate TR, n (%) | 55 (78.6%) | 33 (82.5%) | 22 (73.3%) | 0.355 |
| 12-month | Overall (n = 61) | MitraClip Group (n = 34) | No MitraClip Group (n = 27) | p-value |
| Primary Endpoint, n (%) | 27 (38%) | 12 (30%) | 10 (32.3%) | 0.838 |
| Death, n (%) | 10 (14.1%) | 6 (15%) | 4 (12.9%) | 0.801 |
| HF Hospitalizations, n (%) | 19 (31%) | 9 (22.5%) | 10 (32.3%) | 0.357 |
| NYHA Class | 2 (1-2) | 2 (1-2) | 2 (1-2) | 0.078 |
| NYHA III-IV, n (%) | 11 (18.3%) | 7 (20.6%) | 4 (14.8%) | 0.560 |
| LVEF (%) | 30 (25-39) | 28 (24-35) | 33 (25-40) | 0.129 |
| EDV-LV (ml) | 182 (130-233) | 196 (142-247) | 150 (142-247) | 0.058 |
| ESV-LV (ml) | 125 (83-175) | 143 (93-177) | 100 (75-169) | 0.160 |
| Mild-moderate TR, n (%) | 53 (87%) | 29 (85.3%) | 24 (88.8%) | 0.680 |
| PAPs (mmHg) | 37 (32-45) | 35 (31-45) | 37 (31-45) | 0.856 |
Categorical variables are expressed as n (%). Continuous variables are expressed as mean ± SD and in case of skewed distribution has been reported median and IQR. Primary Endpoint, Death and HF Hospitalizations are counted on the total population (71 patients).
Abbreviations: Primary Endpoint (Composite of death + HF hospitalization); HF: Heart Failure. Other abbreviations as in Table 1.